Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,652,924 | 1,951,967 | 1,486,253 | 1,187,109 | 1,963,053 |
| Marketable Securities | 153,589 | 59,058 | 260,965 | 214,434 | 242,969 |
| Receivables | 5,148,565 | 4,871,214 | 4,699,383 | 4,340,146 | 3,824,977 |
| Inventories | 2,144,772 | 2,108,258 | 2,109,275 | 1,896,464 | 1,743,434 |
| Other current assets | 268,413 | 317,602 | 368,108 | 307,673 | 285,727 |
| TOTAL | $9,368,262 | $9,308,099 | $8,923,984 | $7,945,826 | $8,060,160 |
| Non-Current Assets | |||||
| PPE Net | 2,290,613 | 2,272,431 | 2,231,239 | 2,195,979 | 2,112,812 |
| Investments And Advances | 916,403 | 885,863 | 849,086 | 955,449 | 824,361 |
| Intangibles | 9,672,806 | 9,888,091 | 9,930,411 | 10,851,318 | 11,530,948 |
| Other Non-Current Assets | 1,177,339 | 1,107,485 | 1,082,514 | 832,184 | 668,709 |
| TOTAL | $14,057,160 | $14,153,870 | $14,093,250 | $14,834,930 | $15,136,830 |
| Total Assets | $23,425,420 | $23,461,980 | $23,017,250 | $22,780,760 | $23,196,990 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,634,288 | 2,859,665 | 2,286,757 | 2,177,030 | 2,058,622 |
| Accounts payable and accrued liabilities | 1,182,682 | 1,146,847 | 1,144,648 | 1,348,413 | 1,079,819 |
| Other current liabilities | 4,236,408 | 4,529,500 | 3,810,525 | 3,496,053 | 3,367,916 |
| TOTAL | $8,609,815 | $9,013,128 | $7,644,765 | $7,606,876 | $7,325,479 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,080,000 | 2,176,000 | 3,850,724 | 3,864,373 | 4,155,608 |
| Other Non-Current Liabilities | 592,144 | 1,270,566 | 1,258,823 | 1,410,941 | 1,307,673 |
| TOTAL | $3,343,971 | $3,484,347 | $5,148,118 | $5,314,749 | $5,621,562 |
| Total Liabilities | $11,953,790 | $12,497,470 | $12,792,880 | $12,921,620 | $12,947,050 |
| Shareholders' Equity | |||||
| Common Shares | 669,507 | 700,407 | 710,707 | 679,807 | 690,107 |
| Retained earnings | 5,557,721 | 5,595,924 | 5,121,421 | 4,316,790 | 5,478,014 |
| Other shareholders' equity | 4,272,646 | 3,657,554 | 3,373,444 | 3,895,698 | 3,107,074 |
| TOTAL | $11,471,630 | $10,964,500 | $10,224,370 | $9,859,140 | $10,249,940 |
| Total Liabilities And Equity | $23,425,420 | $23,461,970 | $23,017,250 | $22,780,760 | $23,196,990 |